Search Results
You are looking at 1 - 1 of 1 items for
- Author: S Shafaeizadeh x
- Refine by access: All content x
Search for other papers by H Y Li in
Google Scholar
PubMed
Danone Nutricia Research, Singapore, Republic of Singapore
Search for other papers by Y X Liu in
Google Scholar
PubMed
Search for other papers by L Harvey in
Google Scholar
PubMed
Search for other papers by S Shafaeizadeh in
Google Scholar
PubMed
Department of Pediatrics, University Medical Centre Groningen, Groningen, The Netherlands
Search for other papers by E M van der Beek in
Google Scholar
PubMed
Institute of Molecular and Cell Biology, A*STAR, Singapore, Republic of Singapore
School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by W Han in
Google Scholar
PubMed
The prevalence of gestational diabetes mellitus (GDM) is estimated at 14% globally, and in some countries, such as Singapore, exceeds 20%. Both women and children exposed to GDM have an increased risk of later metabolic diseases, cardiovascular disease and other health issues. Beyond lifestyle changes and pharmaceutical intervention using existing type 2 diabetes medications for expecting women, there are limited treatment options for women with GDM; targeting better outcomes of potentially affected infants is unexplored. Numerous animal models have been generated for understanding of pathological processes of GDM development and for development of treatment strategies. These models, however, suffer from limited windows of opportunity to examine risk factors and potential intervention options. By combining short-term high-fat diet (HFD) feeding and low-dose streptozotocin (STZ) treatments before pregnancy, we have established a mouse model with marked transient gestation-specific hyperglycemia, which allows testing of nutritional and pharmacological interventions before, during and beyond pregnancy.